---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030277"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:43:35.088068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q3 2022 revenue $14.5M (+5% YoY); net loss widens to $2.4M

## Summary
- Revenue of $14.5M, up 5% from $13.8M in Q3 2021, driven by 12% biologics growth from OsteoFactor and OsteoVive Plus launches.
- Gross margin improved to 54.6% from 52.2% on better capacity utilization.
- Net loss of $2.4M ($0.03 loss per share) vs. $1.8M ($0.02) in prior-year period.
- Non-GAAP adjusted EBITDA loss of $0.9M, compared to $0.6M loss a year ago.
- CEO cited recent $9.75M private placement to support growth and expects full operating capacity by Q1 2023.

## SEC filing metadata
- accession: 0001493152-22-030277
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030277
- JSON: https://secwatch.observer/filing/0001493152-22-030277.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030277.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue $14.5 million, net income $2.4 million, EPS $0.03 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $14.5 million
  - Net income: $2.4 million
  - EPS: $0.03 per share
  - Result: reported results
  source text: by the first quarter of 2023 enabling our team to take advantage of the robust demand environment.” Third Quarter 2022 Financial Results Third quarter 2022 revenue was $14.5 million, compared to $13.8 million for the same quarter in 2021. The increase in revenue was largely attributable to introductions of new products. Gross margin for the third quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315222030277/0001493152-22-030277-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.